Cancer Immunotherapy: Managing Amino Acids during Forced Aetopy| Stephy Publishers

 


SOJ Pediatrics and Clinical Neonatology - (SOJPCN)| Stephy Publishers

Abstract

Cancer patients of all ages experience great satisfaction with initial positive results from first-line therapy. Adjuvant therapy helps decrease the risk of cancer recurring or metastasizing. This review discusses forced atopy as cancer immunotherapy and explores managing select amino acids to starve metastatic cells during forced atopy (many allergies).

Introduction

A common goal in oncology is a treatment protocol that minimizes risk and maximizes success. The overall survival rate of children with solid tumor metastasis (Stage IV) has shown little improvement in that the extent of the relocation of metastatic cells, and their progression, is not well understood. To better understand the limits of metastasis, an alternative treatment strategy is proposed; based on maladaptive immunity. A skin cream having natural and recombinant allergens, and associated with immunologic adjuvants, is vectored into the cancer patient by topical dermal absorption. After that, humoral immunity increases the expression of cross-reactive immunoglobulin-E (IgE) primed effector cells, designed to decrease the incidence and prevalence of endogenous proteins that support the metastatic environment.1

Cancer recurrence or metastasis after first-line therapies is life-threatening. In metastasis, metastatic cells from a primary tumor spread throughout the body, forming secondary tumors that aggressively grow and often cause death. Approximately 90% of cancer deaths are due to metastasis.2



To read more #Pediatrics and #ClinicalNeonatology
https://www.stephypublishers.com/sojpcn/fulltext/SOJPCN.MS.ID.000506.php

More #Openaccessjournals
https://www.stephypublishers.com/

Comments

Popular posts from this blog